Equities analysts expect Johnson & Johnson (NYSE:JNJ) to announce $20.40 billion in sales for the current quarter, according to Zacks Investment Research. Four analysts have issued estimates for Johnson & Johnson’s earnings. The lowest sales estimate is $20.28 billion and the highest is $20.53 billion. Johnson & Johnson posted sales of $20.73 billion in the same quarter last year, which would indicate a negative year over year growth rate of 1.6%. The firm is scheduled to issue its next quarterly earnings results on Tuesday, October 20th.
On average, analysts expect that Johnson & Johnson will report full-year sales of $80.86 billion for the current financial year, with estimates ranging from $80.43 billion to $81.26 billion. For the next financial year, analysts expect that the firm will report sales of $87.73 billion, with estimates ranging from $86.42 billion to $88.93 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that that provide coverage for Johnson & Johnson.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Thursday, July 16th. The company reported $1.67 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.50 by $0.17. The business had revenue of $18.34 billion during the quarter, compared to analysts’ expectations of $17.73 billion. Johnson & Johnson had a net margin of 22.69% and a return on equity of 35.21%. The firm’s revenue for the quarter was down 10.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.58 EPS.
JNJ traded up $0.87 during trading on Tuesday, hitting $147.78. 3,933,279 shares of the stock traded hands, compared to its average volume of 8,528,353. The firm has a market capitalization of $394.13 billion, a P/E ratio of 21.61, a price-to-earnings-growth ratio of 3.32 and a beta of 0.68. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.25 and a quick ratio of 0.99. The firm has a 50-day moving average of $149.34 and a 200 day moving average of $144.18. Johnson & Johnson has a 12-month low of $109.16 and a 12-month high of $157.00.
The company also recently announced a quarterly dividend, which was paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th were issued a $1.01 dividend. The ex-dividend date of this dividend was Monday, August 24th. This represents a $4.04 annualized dividend and a yield of 2.73%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 46.54%.
In related news, EVP Kathryn E. Wengel sold 16,115 shares of the business’s stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $153.52, for a total transaction of $2,473,974.80. Following the completion of the sale, the executive vice president now directly owns 66,658 shares in the company, valued at $10,233,336.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Ashley Mcevoy sold 29,000 shares of the business’s stock in a transaction that occurred on Tuesday, July 28th. The shares were sold at an average price of $147.47, for a total transaction of $4,276,630.00. Following the sale, the executive vice president now owns 21,682 shares of the company’s stock, valued at $3,197,444.54. The disclosure for this sale can be found here. 0.27% of the stock is currently owned by insiders.
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Capital Advisors Inc. OK grew its position in Johnson & Johnson by 2.5% during the second quarter. Capital Advisors Inc. OK now owns 82,301 shares of the company’s stock valued at $12,144,000 after buying an additional 1,986 shares during the period. Garde Capital Inc. grew its position in Johnson & Johnson by 5.8% during the second quarter. Garde Capital Inc. now owns 3,602 shares of the company’s stock valued at $507,000 after buying an additional 198 shares during the period. Bridgeway Capital Management Inc. grew its position in Johnson & Johnson by 1.4% during the second quarter. Bridgeway Capital Management Inc. now owns 79,812 shares of the company’s stock valued at $11,224,000 after buying an additional 1,100 shares during the period. Lumbard & Kellner LLC bought a new position in shares of Johnson & Johnson in the second quarter worth approximately $210,000. Finally, Toronto Dominion Bank boosted its position in shares of Johnson & Johnson by 0.4% in the second quarter. Toronto Dominion Bank now owns 2,623,874 shares of the company’s stock worth $267,688,000 after purchasing an additional 10,627 shares during the period. Institutional investors own 67.44% of the company’s stock.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Featured Story: Yield Curve
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.